vaxcyte stock: PCVX overview

Vaxcyte, Inc. (PCVX) stock

Vaxcyte stock is the Nasdaq-listed equity of Vaxcyte, Inc. (ticker: PCVX), a U.S.-based clinical-stage biotechnology company focused on pneumococcal conjugate vaccines and other vaccine candidates. Vaxcyte stock is categorized in the biotechnology sector and typically moves on clinical and regulatory news, financing activity, and broader biotech market sentiment.

As of 2026-01-28, according to Reuters, Vaxcyte stock trades on the Nasdaq under the symbol PCVX and is commonly covered by retail and institutional market data providers.

Company overview

Vaxcyte, Inc. is a clinical-stage vaccine company founded in 2016 and headquartered in Emeryville, California. The company develops next-generation pneumococcal conjugate vaccines and other immunotherapies using proprietary platform technologies. Senior leadership has included executives with vaccine development and commercial experience; the board and management combine scientific and commercial backgrounds to advance late-stage programs.

Vaxcyte's core technology centers on protein-based conjugation and a cell-free protein synthesis platform known as XpressCF, which enables rapid manufacturing and design of conjugated vaccines. The company's primary therapeutic focus has been pneumococcal disease prevention across infant and adult populations, with lead programs designed to offer broader serotype coverage and manufacturing advantages versus incumbents.

Business and product pipeline

Vaxcyte's pipeline and platform are central to how investors assess vaxcyte stock. The company has pursued several lead programs and additional targets supported by its XpressCF platform.

Lead vaccine candidates

• VAX-24: VAX-24 is a pneumococcal conjugate vaccine candidate intended to expand serotype coverage for adult and pediatric use. The program has been positioned as a potential successor or complement to existing pneumococcal vaccines by targeting additional serotypes responsible for invasive pneumococcal disease. As of 2026-01-28, clinical development status and regulatory timing reported by company press releases and market sources influence vaxcyte stock movement.

• VAX-31 (or alternate adult formulation): VAX-31 is an adult-focused pneumococcal vaccine candidate designed for older adult immunization, with trials focused on safety, immunogenicity, and comparability to market standards. Positive or negative readouts for these pivotal trials are material events for vaxcyte stock.

These lead programs are commonly described in public filings and press releases. Investors following vaxcyte stock monitor trial phase transitions (e.g., pivotal/Phase 3 starts and primary endpoint readouts), manufacturing scale-up progress, and immunogenicity comparisons to competitors.

Other pipeline programs and platform

Beyond pneumococcus, Vaxcyte has explored other indications such as Group A Streptococcus (GAS) and targets related to periodontal disease vaccines in earlier-stage research. The company’s XpressCF cell-free protein synthesis and conjugation platform is intended to accelerate antigen design, improve consistency, and reduce manufacturing complexity compared with some traditional methods.

The platform-level potential — ability to support multiple programs from a single manufacturing approach — is often cited by analysts when valuing vaxcyte stock, though platform value depends on successful clinical outcomes and eventual commercial execution.

Stock market information

Ticker and exchange

• Ticker: PCVX
• Exchange: Nasdaq
• Sector classification: Biotechnology / Life Sciences / Medical Research

When searching quotes for vaxcyte stock, common quote conventions include last trade price, bid/ask, previous close, day and 52-week ranges, and market capitalization. Major financial websites and brokerage platforms provide these metrics with varying delays; some offer near real-time feeds for customers.

Key market data (market cap, shares, float)

Typical quote pages for vaxcyte stock show market capitalization, shares outstanding, and float. Market capitalization is calculated as shares outstanding multiplied by share price and changes with price movements and share issuances. Shares outstanding and free float change when the company raises capital, issues stock-based compensation, or insiders trade shares.

As of 2026-01-28, major market data providers such as MarketWatch, Barchart, and SoFi list headline metrics for vaxcyte stock; readers should refer to the latest filings and quote pages for precise numbers. Many financial portals label quotes as delayed (e.g., 15–20 minutes) unless a user accesses a real-time feed via a broker.

Trading characteristics

Biotech equities like vaxcyte stock typically exhibit higher volatility than broad-market equities. Daily trading volume for vaxcyte stock can vary substantially around news events: clinical readouts, regulatory announcements, and financing disclosures often drive spikes in volume. Investors frequently monitor average daily volume, short interest, and options activity (where available) to gauge market sentiment.

Short interest and the presence of derivative markets can amplify price moves. Because vaxcyte stock represents a clinical-stage company, its volatility profile is shaped by binary clinical outcomes and financing needs that influence share supply.

Price history and notable movements

Historical price range and volatility

Vaxcyte stock has experienced multi-year price volatility typical of small- and mid-cap biotech firms. The 52-week high and low reported on public quote pages provide a snapshot of recent volatility but can change quickly during significant news cycles. Historical price swings for vaxcyte stock have reflected progress (or setbacks) in clinical trials, investor financing events, and broader sector rotations.

Events driving major price changes

Major price moves in vaxcyte stock have historically been driven by:

• Clinical trial readouts and topline data releases. Positive immunogenicity or safety data can trigger sharp rallies; disappointing or delayed readouts can cause rapid declines.
• Regulatory interactions and submissions. News of regulatory acceptance of a filing, or unexpected regulatory questions, influences valuation.
• Equity raises and dilution. Announced share offerings or large financing rounds typically put downward pressure on vaxcyte stock as supply increases.
• Partnership and commercial news. Licensing deals, manufacturing agreements, or purchase commitments can provide validation and move the share price upward.

As an example of how timing matters: when a biotech releases positive Phase 2 or pivotal data, vaxcyte stock can spike in intraday trading; conversely, a broad sector selloff in biotechnology can push shares down independent of company-specific fundamentals.

Financial performance

Revenue and profitability

Vaxcyte, like many clinical-stage biotechs, has historically reported limited or no product revenue. Revenue recognition typically depends on partnerships, milestone payments, or future product sales. Operating costs are dominated by research and development and clinical expenses, which result in recurring operating losses and negative earnings per share until commercial products generate revenue.

When evaluating vaxcyte stock, analysts look for changes in revenue sources (e.g., licensing deals) and trends in R&D spend that indicate progression through clinical milestones.

Balance sheet and cash position

For clinical-stage companies, cash runway is a critical metric. Vaxcyte’s balance sheet items of interest include cash and cash equivalents, short-term investments, and debt. Financing activities — public equity offerings, at-the-market (ATM) programs, or convertible financings — are common ways to extend runway.

As of 2026-01-28, market coverage from sources like SoFi and MarketWatch highlights that cash burn, upcoming trial costs, and expected milestone timelines are material to forecasts for vaxcyte stock. Large financings can increase shares outstanding and dilute existing investors, which is an important consideration for holders of vaxcyte stock.

Analyst coverage and market sentiment

Analysts covering vaxcyte stock typically publish ratings (Buy / Hold / Sell equivalents) and price targets based on clinical prospects, assumed timelines, and market opportunity for pneumococcal vaccines. Coverage levels vary among brokerages and independent research firms.

Analyst notes can act as catalysts for vaxcyte stock when they contain changes in clinical probability, updated revenue assumptions, or new partnership information. Consensus estimates and price-target medians are commonly reported on aggregator sites; however, these estimates change with new data.

Corporate actions and governance

Equity offerings and dilution

Vaxcyte has utilized equity financings, like many clinical-stage firms, to fund R&D and trials. Announcements of shelf registrations, follow-on offerings, or at-the-market sales can increase the share count and affect vaxcyte stock performance. Investors monitor the timing, size, and purpose of such offerings because they influence dilution risk and runway expectations.

Insider transactions and board/management

Insider buying or selling activity — trades by executives, directors, and major stockholders — is noted by investors as a governance signal. Material insider purchases may be interpreted as confidence in pipeline prospects, while significant insider sales can create questions about timing or personal liquidity needs. Board composition and management experience in vaccine development are additional governance factors that influence perceptions of vaxcyte stock.

Ownership and institutional holders

Institutional ownership, including mutual funds, pension funds, and specialized biotech investors, often represents a material portion of vaxcyte stock. Large institutional holders can improve liquidity but may also lead to concentrated positions that influence trading dynamics.

Insider ownership trends — percent held by management and board — are also tracked. A substantial insider stake can align incentives with long-term value creation, while low insider ownership may prompt additional scrutiny.

Risks and investment considerations

This section provides neutral, factual risk categories that commonly affect companies like Vaxcyte and the market for vaxcyte stock:

• Clinical risk: Trial failures, safety signals, or lack of efficacy can materially reduce value.
• Regulatory risk: Delays or adverse feedback from regulatory bodies impact timelines and approval chances.
• Competitive risk: Existing pneumococcal vaccine manufacturers and new entrants create pricing and market-share challenges.
• Commercialization risk: Even with approval, market uptake, payer acceptance, and manufacturing scale-up determine product economics.
• Financing and dilution risk: Need for additional capital can result in equity raises and dilution for current shareholders, which impacts vaxcyte stock.
• Sector correlation: Biotech stocks often move together based on macro liquidity, risk appetite, and sector-specific news.

All readers should treat these as factual risk categories, not individualized investment advice.

How to trade / invest

• Exchange and ticker: Vaxcyte stock trades on the Nasdaq under the symbol PCVX.
• Buying shares: Investors can buy shares through licensed brokerages or trading platforms that provide Nasdaq access. When searching for vaxcyte stock, confirm the ticker PCVX and the exchange listing.
• Options: For qualified investors, listed options may exist on major U.S. options exchanges; availability varies with liquidity and exchange listings.
• Quotes and data: Use reputable brokerages or market-data providers for real-time or near–real-time quotes. Many retail portals provide delayed quotes highlighted as such.

Practical cautions: always confirm price and order execution details with your broker before trading. This article is informational and not investment advice.

Bitget note: For readers interested in trading services and custodial features, Bitget provides spot trading, derivatives, and wallet services tailored to a range of asset classes. If you use a trading platform, ensure it supports Nasdaq equities and follow platform-specific onboarding and compliance steps.

Media coverage and market reaction

Financial media and news outlets regularly report on vaxcyte stock when material events occur. Examples of triggers that attract coverage include clinical data releases, regulatory filings, executive changes, and financing announcements. Market reaction often follows headlines closely, with intraday volatility on major news.

As of 2026-01-28, aggregated market commentary from Business Insider, MarketWatch, and Reuters shows that news-driven spikes and drops in vaxcyte stock are common; investors often consult multiple sources to confirm details and context before reacting.

Regulatory and clinical milestones

Key milestones that materially affect the valuation of vaxcyte stock include:

• Phase transition events (e.g., start of pivotal trials or initiation of Phase 3 activity).
• Topline and complete data readouts for pivotal or registrational trials.
• Regulatory submissions such as Biologics License Applications (BLA) or Marketing Authorization Applications (MAA).
• Regulatory approvals or complete response letters from agencies like the U.S. FDA or EMA.
• Manufacturing scale-up, inspection outcomes, or supply agreements that affect commercial readiness.

Each milestone provides new information on safety, efficacy, and commercial viability that markets price into vaxcyte stock.

See also

• Pneumococcal vaccines
• Biotech investing basics
• Nasdaq listing rules and market data
• Vaccine clinical development pathways

References and further reading

As of specified reporting dates, the following public sources commonly provide market data, news, and company information related to vaxcyte stock:

• Robinhood (market quotes and stock profile) — see platform quote pages for PCVX.
• Public.com (investor notes and discussion on PCVX).
• MarketWatch (quote pages and news summaries for vaxcyte stock).
• MSN / Microsoft Money (aggregated market data for PCVX).
• Reuters (company news and filings coverage). As of 2026-01-28, Reuters provides ongoing coverage of Vaxcyte corporate developments.
• SoFi (educational materials and quote data for vaxcyte stock).
• Barchart (technical data, volumes, and historical charts for PCVX).
• Business Insider / Markets Insider (market reaction and analyst commentary that may mention vaxcyte stock).
• Stocklytics (quantitative metrics and sentiment for PCVX).

Note: Where a date is material, articles and quotations above include the reporting date in the text (for example, “As of 2026-01-28, according to Reuters…”). For the latest price, market-cap, volume, and analyst coverage numbers for vaxcyte stock, consult the listed sources directly and cross-check with company filings.

Notes for editors / usage

• Keep market metrics current. Update market capitalization, share count, 52-week range, daily volume, and analyst ratings on a regular schedule and attribute the date and source used.
• This article covers an equity security (vaxcyte stock, PCVX) and should not be conflated with non-financial uses of the Vaxcyte name.
• Avoid using unverified numerical claims without sourcing. If including specific figures (market cap, daily volume), attribute them and include the date in the same sentence.
• Maintain neutral tone and avoid investment recommendations. The article is informational; readers should perform their own due diligence.

Final notes and practical next steps

If you follow vaxcyte stock, create a simple tracking checklist: verify the ticker (PCVX), monitor official company press releases for trial and regulatory updates, and watch scheduled earnings and investor presentations. For live trading, use regulated brokerages that provide Nasdaq access and verify quote delays.

Explore Bitget for trading and custody services if you are seeking a platform to manage trades and wallets. For more company-specific documents, review Vaxcyte’s SEC filings and official press releases, and consult the market-data providers noted above for up-to-date metrics.

Further exploration: check the latest clinical trial registries, company investor relations announcements, and analyst reports to build a timeline of upcoming catalysts that could affect vaxcyte stock.